¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20
±³À°ÀÏÀÚ : 2020-11-20
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2020 KALC International Conference      
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ½ÉÇöÁ¤ 
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:00~08:40 Tumor Infiltrating Lymphocytes and the Microenvironment as Biomarkers for Lung Cancer  David Rimm(Yale University School of Medicine) 
È޽Ġ11¿ù 20ÀÏ  08:40~08:50 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 08:50~09:30 Present and Future Perspectives of First-Line Checkpoint Inhibitor for Stage IV Nonsmall Cell Lung Cancer  David Carbone(The Ohio State University) 
È޽Ġ11¿ù 20ÀÏ  09:30~09:40 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 09:40~10:05 Harms, benefits and cost effectiveness of lc screening  Harry J. de Koning(Erasmus University Medical Center) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:05~10:30 LDCT Screening in Non-Smokers in Taiwan  Pan-Chyr Yang(National Taiwan University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:30~10:55 Imaging Biomarkers in Lung Cancer Screening  ±¸Áø¸ð(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 10:55~11:20 Liquid Biomarkers in Lung Cancer Screening  À̰迵(°Ç±¹ÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  11:20~11:30 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 11:30~12:20 Is it time for a paradigm shift in first line treatment of advanced NSCLC?  ±èÇý·Ã(¿¬¼¼ÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  12:20~12:40 Break&ÃÑȸ  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 12:40~13:05 Predictive Biomarkers for Efficacy of Immune Checkpoint Blockades in Lung Cancer  David Carbone(The Ohio State University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:05~13:30 Translation Research in Immunotherapy for Lung Cancer  Hidetoshi Hayashi(Kindai University) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:30~13:55 Is HyperProgression Real, or How Do We Prepare for It?  ¼±Á¾¹«(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 13:55~14:20 If Less Is Good, More Is Better_Combination of ImmunoTx  ÀÌ´ëÈ£(¿ï»êÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  14:20~14:30 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:30~14:55 Evolution of Acquired Resistance to Targeted Therapies for Lung Cancer  Aaron Hata(Massachusetts General HospitalHarvard Medical School) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 14:55~15:20 Treatment for Advanced ALK, ROS1-Rearranged Lung Cancer  ±èµ¿¿Ï(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:20~15:45 Treatment for Advanced MET, RET-Altered Lung Cancer  Yasushi Goto(National Hospital Organization Kyushu Cancer Center) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 15:45~16:10 Treatment for Other Minor Mutations-Positive Advanced Lung Cancer  °­ÀºÁÖ(°í·ÁÀÇ´ë) 
È޽Ġ11¿ù 20ÀÏ  16:10~16:20 Break  () 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 16:20~16:45 E-Cigarettes and Vaping-Related Lung Injury  Jay H. Ryu(Mayo Clinic College of Medicine and Science) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 16:45~17:10 Current Status of Smoking Cessation with Heated Tobacco Products use in Japan  Takahiro Tabuchi(Osaka international Cancer institute) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 17:10~17:35 Current status of smoking cessation program in Korea and COVID-19 risk in smokers  ÃµÀº¹Ì(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È­»ó°­ÀÇ 17:35~18:00 Pharmacotherapy for Smoking Cessation and Nicotine Dependence  ÃÖÇý¼÷(°æÈñÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÇǺΰúÀÇ»çȸ Á¦2ȸ ´ëÀü/¼¼Á¾/Ãæû Çмú ½ÉÆ÷Áö¿ò : 2020-11-21
´ÙÀ½±Û ´ëÇÑÆó¾ÏÇÐȸ (¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-19
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
283 ´ë±¸ ´ëÇѽÅÀåÇÐȸ ´ë±¸-°æºÏÁöȸ ¿¬¼ö °­Á : 2018-09-20 0 654 2018-07-28
282 ¼­¿ï °Ç±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-20 0 387 2018-07-28
281 ¼­¿ï [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] 4Â÷ »ê¾÷Çõ¸í°ú ÀÇ·áÀÇ ¹Ì·¡ : 2018-09-20 0 634 2018-07-28
280 ¼­¿ï ¼­¿ïƯº°½ÃÀÇ»çȸ Á¦5Â÷ ȸ¿ø¿¬¼ö±³À°(Áø´Ü¸í¿¡ µû¸¥ ÀûÀýÇÑ Ã³¹æ) : 2018-09-20 0 847 2018-07-28
279 °­¿ø ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø Á¦ 130ȸ ¼ÒÈ­±â¼¾ÅÍ ¿¬¼ö±³À° : 2018-09-19 0 734 2018-07-28
278 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-19 0 502 2018-07-28
277 ¼­¿ï ¼ÛÆı¸(4Â÷) °³¿øÀÇ ¿¬¼ö±³À°(¿äÅëȯÀÚ, °ñ´Ù°øÁõ) : 2018-09-18 0 506 2018-07-28
276 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ¾È°úÁö¿ªÀÇ»ç Áý´ãȸ : 2018-09-18 0 519 2018-07-28
275 °æ±â Â÷ÀÇ°úÇдëÇб³ºÐ´çÂ÷º´¿ø ³ì³»Àå : 2018-09-18 0 658 2018-07-28
274 ´ë±¸ ´ëÇѽŰæ°úÇÐȸ ´ë°æÁöȸ - ´ë°æ½Å°æ°úÀÇ»çȸ °øµ¿ ½ÉÆ÷Áö¿ò : 2018-09-18 0 1,497 2018-07-28
273 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-18 0 619 2018-07-28
272 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-17 0 425 2018-07-28
271 °æ±â Á¦ 1ȸ ¾ÆÁִ뺴¿ø ½ÅÀå³»°ú ¿¬¼ö°­Á : 2018-09-16 0 2,100 2018-07-28
270 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Á¦53Â÷ ¾Ë·¹¸£±â ±³À°°­Á : 2018-09-16 0 569 2018-07-28
269 ¼­¿ï 2018³â Á¦3ȸ »ï¼º¼­¿ïº´¿ø ¿Ü°ú ½ÉÆ÷Áö¿ò : 2018-09-16 0 932 2018-07-28
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷